<DOC>
	<DOCNO>NCT02900183</DOCNO>
	<brief_summary>Patients Alpha-1 Antitrypsin Deficiency ( AATD ) enrol receive multiple dos ARC-AAT Injection . All subject require pre-dose biopsy biopsy post last dose .</brief_summary>
	<brief_title>Safety , Tolerability Effect ARC-AAT Injection Circulating Intrahepatic Alpha-1 Antitrypsin Levels</brief_title>
	<detailed_description>This multi-center , multi-dose study evaluate safety , tolerability effect intrahepatic circulate Alpha-1 Antitrypsin ( AAT ) level ARC-AAT Injection , administer intravenously . Participants sign Institutional Review Board/Ethics Committee ( IRB/EC ) approve informed consent form meet protocol eligibility criterion receive multiple intravenous dos ( 7 total dos administer every 28 day ) ARC-AAT Injection . Patients previously , currently never receive AAT augmentation therapy acceptable enrollment . All subject require pre-dose biopsy post-dose biopsy complete last dose early termination applicable . For participant duration study clinic visit approximately 49 week , begin Screening period Day 287 End-of-Study ( EOS ) visit . The following evaluation perform regular interval throughout study : medical history , physical examination , bee venom allergy blood test , vital sign measurement ( blood pressure , temperature , heart rate , respiratory rate ) , weight , adverse event monitoring , electrocardiogram ( ECGs ) , pregnancy test ( female ) , concurrent medication evaluation , pulmonary function testing , clinical laboratory test include hematology , coagulation , chemistry , FibroTest , anti-drug antibody , drug screen , serum AAT level , liver biopsy , FibroScan , urinalysis .</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Male nonnursing female patient 1875 year age , inclusive , time Screening Previous diagnosis PiZZ genotype Alpha1 Antitrypsin Deficiency ( AATD ) Nonsmoker ( daily cigarette smoker ) least three year current nonsmoking status confirm urine cotinine screen . Highly effective , double barrier contraception ( male female partner ) study 3 month follow last dose ARCAAT Injection Suitable venous access blood sample Known diagnosis hepatic fibrosis cause AATD History poorly control autoimmune disease , history autoimmune hepatitis Human immunodeficiency virus ( HIV ) infection Seropositive Hepatitis B virus ( HBV ) Hepatitis C virus ( HCV ) Uncontrolled hypertension History cardiac rhythm disturbance Symptomatic heart failure , unstable angina , myocardial infarction , severe cardiovascular disease , transient ischemic attack ( TIA ) cerebrovascular accident ( CVA ) within 6 month prior study entry History malignancy within last 2 year except adequately treat basal cell carcinoma , squamous cell skin cancer , superficial bladder tumor , situ cervical cancer History major surgery within 1 month Screening Regular use alcohol within one month prior Screening visit Use illicit drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior Screening positive urine drug screen Screening Use investigational agent device within 30 day prior dose current participation investigational study involve therapeutic intervention Any clinically significant history/presence uncontrolled systemic disease Blood donation ( â‰¥500 mL ) within 7 day prior study treatment administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>